CAS: 2219325-28-5

Compound 2i: potent TB inhibitor, effective against resistant strains, MIC < 0.016 μg/mL, good oral bioavailability.

Tuberculosis inhibitor 3 is a synthesized chemical compound designed to target the Mycobacterium tuberculosis bacterium, which is the causative agent of tuberculosis. This inhibitor is derived through advanced chemical synthesis techniques, involving the modification of specific molecular structures to enhance its binding affinity and specificity toward the bacterial cellular targets. The mode of action of Tuberculosis inhibitor 3 involves disrupting essential biochemical pathways within the bacterium. It specifically binds to a critical enzyme or protein involved in the bacteria's metabolic process necessary for survival and replication. By inhibiting this key pathway, the compound effectively reduces bacterial growth and proliferation, contributing to its potential as a therapeutic agent. The primary application of Tuberculosis inhibitor 3 lies in its use as a research tool for studying the molecular biology of Mycobacterium tuberculosis. It serves as a valuable component in the development of new therapeutic strategies and drug discovery processes aimed at controlling or eradicating tuberculosis. Furthermore, its use in laboratory settings can help elucidate the mechanisms of drug resistance and guide the design of novel compounds with enhanced efficacy against resistant strains of tuberculosis.